A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

This is a global, phase 3 multicenter, randomized, double‐blind, placebo‐controlled,parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinibin adult participants with severe CPUO.The design includes 4 periods, for a total duration of up to 60 weeks: ‐ Screening period: up to 4 weeks. ‐ Double‐blind treatment period (treatment period 1, TP1): 24 weeks of double‐blindtreatment with remibrutinib or matching placebo ‐ Open‐label treatment period (treatment period 2, TP2): 28 weeks of open‐labeltreatment with remibrutinib. The participants randomized to the placebo arm will beswitched to remibrutinib at Week 24. ‐ Safety follow‐up period: 4 weeks of treatment‐free safety follow‐up.